trending Market Intelligence /marketintelligence/en/news-insights/trending/l93geeatyn4dolgke9qmpa2 content esgSubNav
In This List

Replimune adds director

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Replimune adds director

Replimune Ltd. named Hyam Levitsky to the board as a nonexecutive director.

Previously, Levitsky served as executive vice president of research and chief scientific officer at Juno Therapeutics Inc., which was recently acquired by Celgene Corp.

Woburn, Mass.-based Replimune Group is a biotechnology company developing oncolytic immunotherapies.